Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

• Pneumococcal Disease
• 13-valent Pneumococcal Vaccine

• Biological: 13-valent Pneumococcal Conjugate Vaccine
  
  4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)
• Biological: 13-valent Pneumococcal Conjugate Vaccine
  
  3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)
• Biological: 13-valent Pneumococcal Conjugate Vaccine
  
  2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)
• Biological: 13-valent Pneumococcal Conjugate Vaccine
  
  2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )
• Biological: 13-valent Pneumococcal Conjugate Vaccine
  
  1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)

• Experimental: Group1
  
  Subjects 6 weeks to <10 months of age with 0 prior dose of Prevnar.
  Intervention: Biological: 13-valent Pneumococcal Conjugate Vaccine
• Experimental: Group 2
  
  Subjects <12 months of age with 1 prior dose of Prevnar.
  Intervention: Biological: 13-valent Pneumococcal Conjugate Vaccine
• Experimental: Group 3
  
  Subjects <12 months of age with 2 prior doses of Prevnar.
  Intervention: Biological: 13-valent Pneumococcal Conjugate Vaccine
• Experimental: Group 4
  
  Subjects ?12 months to <2 years of age.
  Intervention: Biological: 13-valent Pneumococcal Conjugate Vaccine
• Experimental: Group 5
  
  Subjects ?2 years to <5 years of age
  Intervention: Biological: 13-valent Pneumococcal Conjugate Vaccine

Inclusion Criteria:

• Male or female infants 6 weeks to < 5years of age in good health, available for the entire study period and reachable by phone, parents able to complete all relevant study procedures.
• Infants who have received Prevnar are eligible to participate, but this is not required.
• Infants participating in the blood draws must live in a specific identified area (Yukon Kuskokwim Delta region)

Exclusion Criteria:

• Contraindication to vaccination with pneumococcal vaccine or allergic reaction to any vaccines or vaccine related components, immune deficiency, bleeding disorder or major known congenital malformation.